Want to see BOLT full AI Analyst Report?
Top Page
Bolt Biotherapeutics
(NASDAQ:BOLT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▲(0.00% Upside)
Action:Reiterated
Date:10/24/26
The score is held down primarily by weak financial performance (large losses, significant cash burn, and a more leveraged balance sheet with debt exceeding equity). Technicals provide partial support with improving short-to-medium term momentum, but valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Extended Funding Runway
The financing materially extends Bolt’s ability to operate and advance programs without an immediate funding gap. A runway into 2028 supports multiple clinical and preclinical milestones, gives management more flexibility, and reduces near-term dependence on repeated capital raises.
Negative Factors
Revenue Contraction
Falling revenue on a very small base, combined with a large net loss, shows that Bolt has not yet established a durable commercial earnings stream. Continued operating losses limit internal funding capacity and leave future progress dependent on pipeline execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Funding Runway
The financing materially extends Bolt’s ability to operate and advance programs without an immediate funding gap. A runway into 2028 supports multiple clinical and preclinical milestones, gives management more flexibility, and reduces near-term dependence on repeated capital raises.
Read all positive factors
Bolt Biotherapeutics (BOLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.69M
Dividend Yield0.06%
Average Volume (3M)456.95K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth12.79%
EPS Growth37.93%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.00
Shares Outstanding1,926,345
10 Day Avg. Volume1,296,317
30 Day Avg. Volume456,947
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-0.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-18.27
Revenue Forecast (FY)$133.33K
Bolt Biotherapeutics Business Overview & Revenue Model
Company Description
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate c...
How the Company Makes Money
As a clinical-stage biotechnology company, Bolt Biotherapeutics has historically generated little to no recurring product revenue and primarily funds operations through external financing. The company’s cash inflows have generally come from (1) ca...
Bolt Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.70M | 7.70M | 7.69M | 7.88M | 5.73M | 1.26M |
| Gross Profit | 4.50M | 6.20M | 7.69M | -53.67M | -67.39M | -74.39M |
| EBITDA | -27.82M | -32.09M | -66.45M | -67.34M | -86.43M | -97.40M |
| Net Income | -28.74M | -33.38M | -63.12M | -69.20M | -88.10M | -98.59M |
Balance Sheet | ||||||
| Total Assets | 40.34M | 56.75M | 99.63M | 159.78M | 227.81M | 307.72M |
| Cash, Cash Equivalents and Short-Term Investments | 17.60M | 27.50M | 47.32M | 102.19M | 168.89M | 186.22M |
| Total Debt | 21.62M | 22.96M | 25.21M | 20.22M | 22.61M | 24.36M |
| Total Liabilities | 27.70M | 30.24M | 42.43M | 47.04M | 56.30M | 57.60M |
| Stockholders Equity | 12.64M | 26.50M | 57.20M | 112.74M | 171.51M | 250.12M |
Cash Flow | ||||||
| Free Cash Flow | -31.54M | -39.92M | -61.33M | -69.73M | -78.46M | -59.40M |
| Operating Cash Flow | -31.45M | -39.85M | -61.29M | -69.53M | -76.50M | -57.07M |
| Investing Cash Flow | 34.65M | 44.30M | 57.58M | 71.04M | 57.86M | -232.20M |
| Financing Cash Flow | 30.00K | 19.00K | 108.00K | 253.00K | 503.00K | 311.11M |
Bolt Biotherapeutics Technical Analysis
Positive
4.00
Price Trends
3.87
Positive
3.98
Positive
4.50
Positive
Market Momentum
0.45
Negative
81.39
Negative
59.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Positive. The current price of 4 is below the 20-day moving average (MA) of 4.14, above the 50-day MA of 3.87, and below the 200-day MA of 4.50, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 81.39 is Negative, neither overbought nor oversold. The STOCH value of 59.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BOLT.
Bolt Biotherapeutics Risk Analysis
Bolt Biotherapeutics disclosed 61 risk factors in its most recent earnings report. Bolt Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bolt Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $12.69M | -0.41 | -126.23% | 0.06% | 12.79% | 37.93% | |
48 Neutral | $4.33M | -1.55 | -40.62% | ― | 33.30% | 40.59% | |
43 Neutral | $2.73M | -0.80 | -34.23% | ― | ― | 85.52% | |
43 Neutral | $9.52M | -0.52 | -91.18% | ― | ― | 81.87% | |
41 Neutral | $337.23K | -0.01 | 455.31% | ― | -74.05% | 73.08% |
* Healthcare Sector Average
BOLT
Bolt Biotherapeutics
6.59
0.35
5.61%
ERNA
Eterna Therapeutics
1.94
-27.81
-93.49%
XBIO
Xenetic Biosciences
1.85
-1.90
-50.67%
MBIO
Mustang Bio
0.36
-1.14
-76.00%
LYRA
Lyra Therapeutics
0.19
-5.84
-96.85%
INAB
IN8bio
0.97
-1.14
-54.05%
Bolt Biotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Bolt Biotherapeutics Completes Prana Merger, Refocuses Pipeline
Positive
Oct 23, 2026
On October 23, 2026, Bolt Biotherapeutics completed a sign‑and‑close reverse merger to acquire Prana Therapies in a stock‑for‑stock transaction, issuing common shares and Series D non‑voting convertible preferred stoc...
Business Operations and StrategyRegulatory Filings and Compliance
Bolt Biotherapeutics Amends Lease, Reduces Facility Obligations
Neutral
Oct 6, 2026
On October 1, 2026, Bolt Biotherapeutics, Inc. entered into a Second Amendment to its lease with HCP LS Redwood City LLC for its corporate office, laboratory and vivarium facilities in Redwood City, California. As part of the amendment, the compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.